Syntopix signs R&D agreement with P&G
R&D specialist Syntopix has announced it has signed a joint development agreement with Procter & Gamble, which will see P&G using Syntopix’s antimicrobial technology with the objective of improving one of its major healthcare brands.
R&D specialist Syntopix has announced it has signed a joint development agreement with Procter & Gamble, which will see P&G using Syntopix’s antimicrobial technology with the objective of improving one of its major healthcare brands.
Financial details were not disclosed although P&G will have the opportunity to commericailse the Syntopix technology developed under the joint agreement.
“This agreement validates our strategy of broadening the number of potential markets available to the antimicrobial expertise of Syntopix to include consumer healthcare, as well as the over the counter and prescription markets associated with treating dermatological conditions,” commented Dr Stephen Jones, Syntopix ceo.